Search results
Results from the WOW.Com Content Network
good. Frequency. 0.2% for those on biphosphonate type drugs >4 years. Medication-related osteonecrosis of the jaw (MON, MRONJ) is progressive death of the jawbone in a person exposed to a medication known to increase the risk of disease, in the absence of a previous radiation treatment.
Myelosuppression, hypokalaemia, cytokine release syndrome, Stevens–Johnson syndrome (uncommon), toxic epidermal necrolysis (uncommon) and pancreatitis (uncommon) Cytarabine. SC, IM, IV, IT. DNA polymerase inhibitor, S-phase specific. Incorporates its metabolites into DNA.
The first list was published in 1977 and included 208 medications. [8] [2] [9] The WHO updates the list every two years. [10] There are 306 medications in the 14th list in 2005, [11] 410 in the 19th list in 2015, [10] 433 in the 20th list in 2017, [12] [13] 460 in the 21st list in 2019, [14] [15] [16] and 479 in the 22nd list in 2021.
A drug overdose (overdose or OD) is the ingestion or application of a drug or other substance in quantities much greater than are recommended. [ 2 ][ 3 ] Typically it is used for cases when a risk to health will potentially result. [ 2 ] An overdose may result in a toxic state or death. [ 3 ]
OLED. An organic light-emitting diode (OLED), also known as organic electroluminescent (organic EL) diode, [ 1 ][ 2 ] is a type of light-emitting diode (LED) in which the emissive electroluminescent layer is an organic compound film that emits light in response to an electric current. This organic layer is situated between two electrodes ...
The osmotic-controlled release oral delivery system (OROS) is an advanced controlled release oral drug delivery system in the form of a rigid tablet with a semi-permeable outer membrane and one or more small laser drilled holes in it. As the tablet passes through the body, water is absorbed through the semipermeable membrane via osmosis, and ...
Modified-release dosage. Modified-release dosage is a mechanism that (in contrast to immediate-release dosage) delivers a drug with a delay after its administration (delayed-release dosage) or for a prolonged period of time (extended-release [ER, XR, XL] dosage) or to a specific target in the body (targeted-release dosage). [1]
Risk Evaluation and Mitigation Strategies. Risk Evaluation and Mitigation Strategies (REMS) is a program of the US Food and Drug Administration for the monitoring of medications with a high potential for serious adverse effects. REMS applies only to specific prescription drugs, but can apply to brand name or generic drugs. [1]